iBio, Inc. has achieved a critical technology transfer milestone verified by an independent third party lab. The validation milestone confirmed that the iBioLaunch system can be used by third parties to replicate production of commercial yields of targeted biopharmaceuticals, including vaccines and therapeutics, without assistance from iBio.   “In light of our recently announced commercial collaborations, this is an important demonstration that our technology can be readily utilized by oth...